#

Biotechnology

: 158
Playboy has evolved into essentially a brand and licensing company with a growing lingerie retail arm / Photo: Yuphayao Poohs / Shutterstock.com
Small Caps·
Small caps last week: Playboy's pivot, AbCellera trial win, GLP-1 boon for AirSculpt
SolarEdge retreated to a multi-month low after the maker of inverters and other solar equipment called for potentially lower sales in 3Q26 / Photo: Shutterstock.com
Small Caps·
Small caps last week: SolarEdge guidance, Bitdeer contract, Replimune nears approval
Investment bankers have faith in SpaceX, despite the stocks decline following the earnings report. Ron Adar / Shutterstock.com
Review·
A Hot Topic from SpaceX, Burry’s Bleak Outlook, and a Touching “Startup” Born Out of Necessity
The company listed on NASDAQ under the ticker symbol BLSM. Photo: BlossomHill
News·
BlossomHill Therapeutics IPO: Cancer Drug Developer Goes Public
Photo: Seacalm/Shutterstock
News·
Braveheart Bio IPO: Shares in the cardiovascular drug developer are now available
If the drug is approved by the FDA, Compass plans to begin sales in the first half of 2027 / Photo: Compass / LinkedIn
Small Caps·
Compass could be first to U.S. market with psychedelics therapy for depression
An FDA advisory panel voted that results from the study of Replimune’s experimental melanoma treatment are clinically meaningful / Photo: Replimune
Small Caps·
Biotech Replimune more than doubles after FDA panel OKs skin cancer treatment
A Cathie Wood ETF has invested in Scribe, a clinical-stage developer of gene therapies for heart diseases / Photo: Facebook / ARK Invest
Small Caps·
Small caps last week: Cathie Wood’s Scribe bet, deals to acquire Forte Bio and CBIZ
Due to a shortage of components, Apple raised prices on Mac computers and iPad tablets in June. Photo: Skorzewiak / Shutterstock
Review·
Apple's Short-Lived Triumph, Non-Banks Battle for Colombia, and a Dinosaur Worth Millions of Dollars
The deal adds Forte’s experimental drug FB102, which Argenx said has potential to address multiple autoimmune diseases / Photo: Unsplash / CDC
Small Caps·
Autoimmune-focused biotech Forte to be acquired by Argenx; stock soars 40%
A Cathie Wood ETF has invested in Scribe, a clinical-stage developer of gene therapies for heart diseases / Photo: LinkedIn / Catherinedwood
Small Caps·
Cathie Wood's ARK Genomic Revolution ETF buys newly public biotech Scribe
BofA cut its price target for Papa Johns shares to $34, 9% below their current market price / Photo: Linkedin.com
Small Caps·
Small caps last week: Papa John's doubts, Perfect goes private, LLY-AtaiBeckley deal
Load more